INTRODUCTION
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world. It is characterized by a highly heterogeneous clinical course, with some patients dying from their disease within months, while others have a normal life expectancy. 1 In recent years, this clinical heterogeneity had been shown to correlate with the pattern of genetic changes. 2 Using modern molecular cytogenetic techniques, genomic aberrations are detected in more than 80% of chronic lymphocytic leukemia (CLL) cases. 3 The most frequent abnormalities are losses of genomic material, namely deletions affecting chromosome bands 13q14, 11q22-q23, 17p13, and 6q21. The most common gains of genomic material affect 12q13, 8q24, and 3q26. 3 Several of these genomic aberrations are among the most important prognostic factors in B-CLL: 17p and 11q deletions are associated with rapid disease progression and short survival times, whereas deletion of 13q14 as single abnormality predicts for longer survival times. 3 The tumor suppressor gene p53 is affected by 17p deletions; ATM (ataxia telangiectasia mutated) is altered in a proportion of cases with 11q deletions, and candidate genes have been found in the critical region of 13q14 deletions. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Another important genetic marker, related to the stage of B-cell differentiation, is the recombination status of variable, diversity, and joining heavy chain immunoglobulin gene segments and the process of somatic hypermutation. Roughly one half of B-CLL cases exhibit somaticallymutated variable heavy chain (VH) genes. 20, 21 As the presence of unmutated VH correlates with a more aggressive clinical course, the question arose whether the diagnosis B-CLL comprises two distinct disease entities. [20] [21] [22] [23] [24] [25] [26] [27] [28] However, the data presented in two recent expression profiling studies 19, 29 reject this proposal based on the large overlap of the transcriptomes of VH-mutated and unmutated cases. While both transcriptomes appeared related to memory B-cells, in both studies a small set of genes was found differentially expressed in VH-mutated versus unmutated cases.
In the present study, a large number of molecularly well-defined B-CLL samples (n ϭ 100) were subjected to genomic-scale expression profiling with respect to the most common genomic aberrations, as well as to VH mutational status. Highly significant B-CLL subtype predictors could be constructed that could be used both for diagnostic and prognostic purposes. Interestingly, the genomic signature for the VH mutational status seems to be sex-related. In addition, our data demonstrate a clear correlation between altered transcript levels and loss or gain of genomic material indicating that a gene dosage effect may exert a pathogenic role in B-CLL.
MATERIALS AND METHODS

Samples
One hundred blood samples were obtained from B-CLL patients; these patients represent a subset of those previously reported. 3 In the present study, 62 patients were male and 38 were female; the age at the time of study ranged from 30 to 87 years (median, 62.5 years). Sixty-two patients had Binet stage A, 33 had stage B, and five patients had stage C disease.
Mononuclear cells from all samples were isolated using Ficoll gradient, snap frozen, and stored at Ϫ80°C or Ϫ196°C. As control samples, CD19ϩ fractions from 11 healthy individuals were purified using MACS CD19 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) from buffy coat preparations obtained randomly from our blood bank after informed consent. With regard to routine diagnostic use and in order to avoid further manipulation, CLL samples used throughout the study were not further manipulated after Ficoll purification, as the median CD19ϩ cell content was 88% (mean, 86% Ϯ 14%).
Genomic Aberrations and VH Mutation Status
All samples were previously characterized for the presence of genomic aberrations and the VH mutation status as described. 3, 26 Briefly, samples were representative for the dominant subgroups defined by genomic aberrations. 3 The numbers of cases from the individual subgroups were: 17p-(n ϭ 10), 11q-(n ϭ 12), ϩ12q (n ϭ 20), 13q-(n ϭ 51), 6q-(n ϭ 9), 13q-as sole aberration (n ϭ 34), and normal karyotype (n ϭ 22). Forty-seven samples were VH-mutated and 53 were VH-unmutated (Table 1) .
Hybridization and Data Acquisition
Starting with approximately 5 g total RNA per sample, double-stranded cDNA was synthesized using the Custom Superscript ds-cDNA Synthesis Kit (Invitrogen, Karlsruhe, Germany). From this template, biotin-labeled cRNA was prepared using the Enzo BioArray High Yield RNA Transcript Labeling Kit (Affymetrix, High Wycombe, United Kingdom), and unincorporated nucleotides were removed using RNeasy columns (Qiagen, Hilden, Germany). Hybridization, washing, and fluorescence staining of human genome U95A or U95Av2 microarrays were carried out according to the manufacturer's instructions (Affymetrix, GeneChip Expression Analysis Technical Manual). The integration of the oligonucleotide fluorescence intensities of each probe set to obtain one expression value per gene was done using Affymetrix Microarray Analysis Suite (version 5.0). Genes with different probe sets on HG-U95A and HG-U95Av2 were omitted from the analysis (51 genes).
Expression Data Preprocessing
Saturation. The dynamic range of Affymetrix raw data is known to exhibit a ceiling varying slightly from experiment to experiment, typically around 45,000 units. Raw intensity values close to the ceiling are likely to be affected by a hardware saturation effect. Therefore, 149 genes exhibiting raw intensities above 43,000 units in at least one sample were excluded from the analysis.
Normalization. Raw expression data were normalized using a nonlinear method as described. 30 Briefly, the method considers pairwise comparisons of all experiments with one reference experiment. Here a control sample was chosen as reference. First, a subset of not differentially expressed genes was determined by selecting all genes with a rank difference between the two experiments below a threshold. A scatter plot 'smoother' (Supsmu, as provided by S-plus, version 3.3; Insightful, Seattle, WA) was applied to this subset for determining the normalizing transformation, which in turn was applied to all gene expression values for the experiment considered. Before normalization, data were converted to logarithmic values, which were further used in all subsequent analyses. Variation filter. A variation filter was applied for selecting informative (ie, significantly varying) genes before unsupervised analysis. The ratio (variance/arithmetic mean) of the logarithmic expression values was used as a criterion with a threshold of 0.35.
Supervised Analysis
Statistical group comparisons. Genomic aberration and VH mutation status each define a partitioning of the samples into two subsets. Significantly differentially expressed genes were determined using the t statistic assuming equal variance in the two groups. For a more precise control of false discoveries, a dataspecific null model was constructed by generating 1,500 modified data sets with permuted class labels. We followed the procedure described previously. 31 Briefly, the t statistic was calculated for each gene according to the known separation into two groups. Genes were sorted by the t statistic. Subsequently, random class label permutations were performed. After each permutation, the t statistic was recalculated and genes were ranked by their score. All scores with a given rank i in any of the permuted data sets define the probability density function of the null model for rank i. As a result, one obtains rank-specific thresholds for t for a given level of significance.
Predictors. Linear and quadratic discriminant analysis (LDA; QDA) as implemented in PartekPro (Partek Inc, St Charles, Missouri) were used for the construction of classifiers. The preselection of genes followed the permutation test described above. In order to further reduce the number of genes, the following iterative method was applied. Two criteria were used to assess the quality of the predictor at each iteration step: (1) performance of the classifier on the complete data set; and (2) performance in a cross-validation test. The algorithm iteratively adds one gene to the classifier until the desired performance is achieved. Usually, for the first two or three genes, an exhaustive search for the optimal combination is feasible. For the construction of predictors using more genes, a genetic algorithm was used. QDA correctly predicts class membership with fewer genes in the majority of cases; however, it performed worse than LDA in the cross-validation test (overprediction). Therefore, only LDA classifiers are reported here.
Unsupervised Analysis
Dimensionality reduction. Principal component analysis (PCA) in gene space was used for calculating three-dimensional projections of samples. PCA maximizes the variance described by a given number of dimensions (principal components), thereby reducing dimensionality with minimal distortion. Here, PCA was done in the subspace of genes either differentially regulated between known groups or varying across all samples considered.
Hierarchical clustering. Objects (genes or samples, respectively) were clustered with Ward's method, using half square Euclidean distance as similarity measure. Results were visualized with the help of heatmaps and dendrograms. The heatmaps show color-coded expression levels (red ϭ high expression, black ϭ medium expression, and green ϭ low expression). Sample trees are drawn horizontally, and gene trees vertically.
PCA and clustering were performed with Spotfire DecisionSite (Spotfire Inc, Somerville, MA).
RESULTS
Association of Expression Profiles and B-CLL Genetic Subtypes
Microarray-based expression data of 100 B-CLL samples were analyzed considering the following genetic parameters: VH mutation status, 17p13, 11q22-q23, 13q14, and 6q21 deletion, as well as trisomy 12q13. Presence and absence of each of these features divided B-CLL subtypes into two classes (for numbers of samples in each class, see Table 1 ). Table 2 lists the number of differentially expressed genes that were determined for each classification using the rank-specific null model with a significance level of 0.05. For trisomy 12 and the VH status, the classical StudentЈs t test was sufficient, since the permutation approach failed to deliver a t statistic better than calculated using the correct class labels. This indicates a particularly good class separation in these two cases.
A high degree of correlation was observed between the chromosomal localization of differentially expressed genes and the respective genomic aberrations (Fig 1; Table 3 ). Within the group carrying 17p13 deletions, 14 of the 25 most significantly differentially expressed genes were located in chromosome band 17p13, and all of these were downregulated. Among the downregulated genes were the tumor suppressor gene TP53 and GPS2 (G-protein pathway suppressor 2)/AMF1. Concerning the 11q22-q23 deletions, eight of the top 25 genes clustered at the corresponding genomic region and all were downregulated, including the genes for ATM, DDX10, and CASP1. Among the top 25 genes differentially expressed in the 6q deletion group were three genes at locations from 6q13 to 6q16 (ie, MAP3K7, sorting nexin SNX3 and KIAA0776), and one gene mapped at 6q21 (absent in melanoma AIM1), all downregulated. However, 12 of the top 25 genes were members of the histone H2A and H2B families, located at 6p21.3, which were significantly upregulated. Genes affected by the 13q14 
Prediction of Class Membership
Classifiers were calculated by linear discriminant analysis. The number of genes needed to build a predictor with a given performance reflected the power of group separation, as did the number of correctly allocated samples in a cross-validation test (Table 4 ). The predictor variables (genes) are given in the supplementary online material (Table A1). Adding further genes from the same region did not improve predictor performance to the extent that adding genes from other loci (possibly regulated in the opposite direction) did. Figure 2 displays the predictor performance in three dimensions using PCA for dimensionality reduction. It turned out that the easiest case for class prediction was trisomy 12 (five genes, no misclassification), while the most difficult one was VH (12 genes, 4% misclassification).
Unsupervised Analysis
To assess the potential of comprehensive expression data with regard to disease subtyping, we performed unsupervised cluster analyses including the 100 B-CLL and the 11 control samples. A variation filter excluded all genes that were assumed to be uninformative because of little variation across the samples. Both hierarchical clustering and PCA of 43 genes passing the filter showed a similar picture (Fig 3) : The PCA plot (covering 42% variance) separated the control and B-CLL samples on the one hand and male and female samples on the other hand.
Hierarchical clustering distinguished three sample subtrees (Fig 3A, from left to right): (1) A subtree with all female samples (including one control); (2) a subtree with control samples; and (3) a subtree containing mainly male B-CLL samples. Interestingly, the hierarchical clustering, as well as the PCA plot, showed an additional splitting of the male samples into a predominantly VH-mutated and a predominantly VH-unmutated group. The left subtree of male patients contained 16.7% mutated samples, whereas the one to the right included 76.2% mutated samples; overall, there were 45.7% mutated samples among male patients. The female tree contained 51.6% mutated samples. Based on these observations, hierarchical clustering analogous to Figure 3A was done with male and female samples separately. The same filtering conditions were applied and Fig 4B) . In order to confirm the statistic significance, t tests of male mutated versus unmutated and female mutated versus unmutated samples were performed. The first comparison yielded significantly more differentially expressed genes than the second comparison (161 v 11 genes; P cutoff ϭ .001). Using the permutationbased null model, all differentially expressed genes scored better than the 0.01 significance level for male patients. Differentially expressed genes in female patients fell between the 0.5 and the 0.05 significance level (Fig 4C) . The diagrams show up to which rank (by t statistic) differentially NOTE. For a complete listing of differentially expressed genes, see Table A2 (online only) . Abbreviations: NIK, NF-kappa B inducing kinase; ATP, adenosine triphosphate; GTP, guanosine triphosphate; CLL, chronic lymphocytic leukemia; ADP, adenosine diphosphate; VH, variable heavy chain; LDLR, low-density lipoprotein receptor; HMG, high mobility group.
expressed genes are significant at the eg P ϭ .01 level, given the rank-specific null model (confer methods).
DISCUSSION
Cytogenetic abnormalities and mutational status of IgV H genes in B-CLL were previously identified as independent prognostic factors, indicating a complementary role of genomic aberrations and VH mutation status to predict outcome in CLL. 26 In the current study, expression profiles of a large number of B-CLL samples were assessed for both VH mutation status as well as the genomic aberrations 6q, 11q, 13q, and 17p deletion, and trisomy 12, in order to construct predictors based on the expression profiles of a subset of genes.
Class Predictors
As demonstrated in Table 4 , highly significant B-CLL subtype predictors could be constructed for all evaluated NOTE. Number of genes used in each predictor (row 1) and predictor performance (rows 2-5). The genes used for each predictor are listed in Table A1 (online only) . Abbreviations: LDA, linear discriminant analysis; CV, cross-validation. biologic parameters. The number of genes necessary to construct the respective predictors varied between five genes for 17p-, 6q-, ϩ12, and 12 genes for VH status. Interestingly, the percentage of correctly allocated samples is inversely correlated to the number of genes necessary for the predictor. It is noticeable that the genes used for each predictor did not cluster in the regions affected by the genomic aberration, since sets of genes constituting a predictor may represent only one of several possible sets performing equally well, due to the usage of a genetic algorithm for the construction of the predictors.
Genomic Aberrations
A clear correlation between the chromosomal location of differentially expressed genes and the genomic region affected by the most frequent aberrations was observed. This effect could be detected with statistical significance despite the fact that there were unbalanced group sizes. Also, the type of the aberration (trisomy v deletion) correlated with the direction of the changes (ie, up-or downregulation) on the transcript level. Trisomy 12, which usually affects the whole chromosome 12, was related to an increase in transcript levels scattered along the whole chromosome, while 11q and 17p deletions, which affect critical regions in bands 11q22-q23 and 17p13, respectively, were associated with downregulation of transcripts in these circumscribed regions (Fig 1) . Although the 13q deletion was associated with a specific gene expression signature as well, it did not exhibit a strong locus correlation. One possible explanation is that the size of the deletions is, in general, far smaller than that of the other chromosomal deletions. The observation of a clear correlation between altered transcript levels and loss or gain of genomic material is proof-ofprinciple that even without CD19ϩ selection, distinct gene expression signatures can be observed in genetic subgroups of B-CLL. An analogous effect was reported previously for trisomy 8 occurring in a subset of acute myeloid leukemia cases, 32 but not in a study which investigated the effects of the 11q deletion only in B-CLL in a small number of cases. 33 The occurrence of an explicit correlation between genomic aberrations and the deregulation of genes located in the respective chromosomal region to such an extent in B-CLL patients presents a surprising finding and suggests a gene dosage effect as a likely pathogenic factor and a potential pathomechanism in B-CLL.
Since the critical genes of pathogenic relevance have not yet been defined for most of the recurrent aberrations in B-CLL, those genes, which reside in the imbalanced genomic region, and the expression of which deviates in the same direction, provide good candidates for being diseaserelevant. Among these downregulated genes were ATM and p53, both of which are considered genes with pathogenic relevance in B-CLL. ATM was shown to be mutated in a subset of B-CLL cases exhibiting 11q deletion. 4, 7, 10, 34 B-CLL cases with 17p deletion exhibit intragenic mutations of the second p53 allele in the majority of cases, providing strong evidence for its role as a disease gene in B-CLL. 8, 9, 17, 18 Recently, the overlapping pathways of ATM and p53 were investigated by studying the expression profiles of TP53-and ATM-mutant cells after DNA damage. 35 Interestingly, two further genes were found which may be implicated in the pathogenicity of B-CLL, namely GPS2/ AMF1 located on 17p13 and CASP1 at 11q23. Overexpression of GPS2, a modulator of p53 transactivation, resulted in increased apoptosis in cells on exposure to ultraviolet irradiation.
36 Caspase 1 is a transcriptional target of p53 and contributes in part to p53-mediated apoptosis. 37 Thus, downregulation of GPS2 and CASP1 genes is consistent with a proposed defect in apoptosis.
Additionally, significant changes were observed in the expression of genes, which do not map to the affected loci. These might be downstream effectors of the genes directly affected by the loss or gain and may contribute to the disease phenotype as well. For example, deletion of 6q21 is accompanied by elevated expression levels of members of the HIST1 major histone gene locus on chromosome 6 (6p21-p22), which are highly transcribed in proliferating cells.
However, this may be the result of an unrecognized amplicon at locus 6p21-p22.
VH Mutation Status
The impact of the VH mutation status on the transcriptome in B-CLL has been investigated by Klein et al 19 and Rosenwald et al. 29 In both studies, an unsupervised approach failed to yield a partitioning into preferentially VHmutated and preferentially unmutated samples. In contrast, in the present study, hierarchical cluster analysis using a gene set selected by a variation filter revealed such a partitioning. Surprisingly, this partitioning was observed only for samples from male patients. Possible reasons for this observation are the following: (1) the larger number of samples used for this study (100 v 28 and 34 in the studies by Klein et al and Rosenwald et al, respectively); and (2) application and parameterization of a variation filter before clustering: here, a rather stringent variation filter was applied to eliminate as much "noise" as possible, allowing less than 100 genes varying markedly across all experiments to pass. With regard to the genes distinguishing mutated from unmutated samples, there was significant overlap with the data from the two previous studies. Lipoprotein lipase (P Ͻ 4 ϫ 10 Ϫ9 ), dystrophin (P ϭ 2 ϫ 10 Ϫ6 ), ZAP70 (P Ͻ 4 ϫ 10 Ϫ4 ), and BCL7A (P ϭ 4 ϫ 10 Ϫ4 ) show a P value for differential expression less than .001 in Rosenwald et al study and our analysis, as well as a signal-to-noise score greater than 2.0 in Klein et al. Therefore, a similar signature of the two VH subgroups was identified in the current analysis after the omission of CD19ϩ selection as compared to the previous studies. 19, 29 The finding that only male patients could be partitioned into predominantly VH-mutated and unmutated by hierarchical clustering was unexpected and may hint at sex as a novel parameter. Interestingly, an incidence of male predominance among the VH-unmutated group was described in the initial description of the differences in clinical outcome based on IgV H genotype. 23 Thus, sex may indirectly influence clinical outcome and even B-cell maturation and differentiation.
Increasingly, it is recommended to complement classical staging systems and clinical parameters by molecularlydefined prognostic factors. Analysis of genomic aberrations requires fluorescence in situ hybridization while determination of the VH status involves amplification of IgV H genes followed by sequencing. Currently, both methods are not amenable to routine diagnostic use for most laboratories.
Recently, the development of a robust DNA array based on comparative genomic hybridization (matrix-CGH) for the automatic analysis of recurrent genomic imbalances was described. 39 The present study demonstrated the successful construction of combined B-CLL subtype predictors for both genomic aberrations and VH mutation status, and suggest that clinical diagnosis and prognosis can be optimized by including gene expression-based predictors. Of course, it will be important to validate our gene expression predictor in a prospective cohort of patients before its routine implementation in clinical practice. Overall, it is anticipated that in the future, a combination of different microarray technologies will result in even more accurate diagnosis and prognosis for B-CLL.
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